Prevalence of HIV Drug Resistance Mutations among Treatment-Naive People Living with HIV in a Tertiary Care Center in India
Am J Trop Med Hyg. 2024 Mar 5:tpmd230026. doi: 10.4269/ajtmh.23-0026. Online ahead of print.ABSTRACTIndia has the third-largest number of people living with HIV (PLHIV) in the world. A national program provides free access to standard uniform antiretroviral therapy. However, the program is not monitored by comprehensive drug resistance surveys. The aim of this study was to determine the prevalence of HIV drug resistance mutations (DRMs) among treatment-naive PLHIV in a large antiretroviral treatment center of the national program. This cross-sectional study was done in 2017 and involved 200 consecutive treatment-naive PLHI...
Source: The American Journal of Tropical Medicine and Hygiene - March 5, 2024 Category: Tropical Medicine Authors: Shweta Srivastva Jaya Chakravarty Anurag Kumar Kushwaha Source Type: research
Prevalence of HIV Drug Resistance Mutations among Treatment-Naive People Living with HIV in a Tertiary Care Center in India
Am J Trop Med Hyg. 2024 Mar 5:tpmd230026. doi: 10.4269/ajtmh.23-0026. Online ahead of print.ABSTRACTIndia has the third-largest number of people living with HIV (PLHIV) in the world. A national program provides free access to standard uniform antiretroviral therapy. However, the program is not monitored by comprehensive drug resistance surveys. The aim of this study was to determine the prevalence of HIV drug resistance mutations (DRMs) among treatment-naive PLHIV in a large antiretroviral treatment center of the national program. This cross-sectional study was done in 2017 and involved 200 consecutive treatment-naive PLHI...
Source: Am J Trop Med Hyg - March 5, 2024 Category: Infectious Diseases Authors: Shweta Srivastva Jaya Chakravarty Anurag Kumar Kushwaha Source Type: research
Prevalence of HIV Drug Resistance Mutations among Treatment-Naive People Living with HIV in a Tertiary Care Center in India
Am J Trop Med Hyg. 2024 Mar 5:tpmd230026. doi: 10.4269/ajtmh.23-0026. Online ahead of print.ABSTRACTIndia has the third-largest number of people living with HIV (PLHIV) in the world. A national program provides free access to standard uniform antiretroviral therapy. However, the program is not monitored by comprehensive drug resistance surveys. The aim of this study was to determine the prevalence of HIV drug resistance mutations (DRMs) among treatment-naive PLHIV in a large antiretroviral treatment center of the national program. This cross-sectional study was done in 2017 and involved 200 consecutive treatment-naive PLHI...
Source: The American Journal of Tropical Medicine and Hygiene - March 5, 2024 Category: Tropical Medicine Authors: Shweta Srivastva Jaya Chakravarty Anurag Kumar Kushwaha Source Type: research
Comments on: Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis
(Source: Hepatology International)
Source: Hepatology International - March 2, 2024 Category: Infectious Diseases Source Type: research
Preexposure Prophylaxis Adherence Counseling for Cisgender Women
More than a decade after the approval of emtricitabine and tenofovir disoproxil fumarate (F/TDF) for HIV preexposure prophylaxis (PrEP), rates of new HIV infections remain high globally, with most occurring among cisgender women, and exceed the United Nations global targets. In the US, rates of PrEP use are substantially low in cisgender women, with disparities by race and ethnicity and across regions. Concerns about the effectiveness of F/TDF and limited PrEP alternatives complicate efforts to increase the use of PrEP in cisgender women. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - March 1, 2024 Category: General Medicine Source Type: research
HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women
This pooled analysis of postapproval studies examines the association between baseline demographics and other characteristics and PrEP adherence trajectories with HIV incidence in women. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - March 1, 2024 Category: General Medicine Source Type: research
Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy
CONCLUSIONS: TDF therapy is associated with a reduced risk of HCC-related outcomes among patients with HBV-related HCC after curative intent treatment compared with ETV usage.PMID:38423922 | DOI:10.1016/j.jfma.2024.02.011 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - February 29, 2024 Category: General Medicine Authors: Kai-Chun Chang Tung-Hung Su Sih-Han Liao Tai-Chung Tseng Shang-Chin Huang Shih-Jer Hsu Chun-Ming Hong Chen-Hua Liu Hung-Chih Yang Chun-Jen Liu Jia-Horng Kao Source Type: research
Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy
CONCLUSIONS: TDF therapy is associated with a reduced risk of HCC-related outcomes among patients with HBV-related HCC after curative intent treatment compared with ETV usage.PMID:38423922 | DOI:10.1016/j.jfma.2024.02.011 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - February 29, 2024 Category: General Medicine Authors: Kai-Chun Chang Tung-Hung Su Sih-Han Liao Tai-Chung Tseng Shang-Chin Huang Shih-Jer Hsu Chun-Ming Hong Chen-Hua Liu Hung-Chih Yang Chun-Jen Liu Jia-Horng Kao Source Type: research
Response to letter to editor for risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide: a systematic review and meta-analysis
(Source: Hepatology International)
Source: Hepatology International - February 29, 2024 Category: Infectious Diseases Source Type: research
Comparison of the efficacy and safety of TAF, TDF, and LdT to prevent the transmission of hepatitis B in pregnant women: A retrospective study
ConclusionThe application of TDF, TAF, or LdT to immune-tolerant HBV-infected pregnant women in middle –late pregnancy can successfully interrupt MTCT of the HBV virus. However, for all three groups of pregnant women who delivered babies with abnormal prenatal ultrasound screening, an expanded sample size may be needed for further observation. (Source: Immunity, Inflammation and Disease)
Source: Immunity, Inflammation and Disease - February 28, 2024 Category: Allergy & Immunology Authors: Shufang Pan,
Ying Zhang,
Yingfu Zeng,
Chaoshuang Lin Tags: ORIGINAL ARTICLE Source Type: research
Viruses, Vol. 16, Pages 348: HBcAb Positivity as a Risk Factor for Missing HIV RNA Undetectability after the 3TC+DTG Switch
In this study, a comparison analysis was conducted between HBcAb-positive and -negative PLWH regarding HIV-RNA suppression, considering: (1): Target Not Detected (TND) < 20 cp/mL; (2) Target Detected (TD) < 20 cp/mL; and (3) Detectable > 20 cp/mL and <50 cp/mL and >50 copies/mL. A total of 267 patients on 2DR with 3TC-DTG were included. In comparison to HBcAb-negative, HBcAb-positive patients were older (45 years [35–54]) and had a lower CD4+ nadir (248 vs. 349 cells/mmc, p = 0.007). No difference in the maintenance of virological suppression was present ...
Source: Viruses - February 23, 2024 Category: Virology Authors: Vincenzo Malagnino Tiziana Mulas Elisabetta Teti Monica Basso Mario Giobbia Nicholas Geremia Giuliana Battagin Yasmine Abi Aad Jean-Paul Vincensini Marco Iannetta Saverio Giuseppe Parisi Loredana Sarmati Karine Lacombe Tags: Brief Report Source Type: research
A pilot program of HIV pre-exposure prophylaxis in Thai youth
ConclusionsDaily oral PrEP with FTC-TDF in high-risk Thai adolescents is feasible, accepted, well-tolerated, and had no increased risk compensation; however, low adherence was a major challenge. Adolescent-specific PrEP strategies including long-acting modalities are needed for successful HIV prevention. (Source: PLoS One)
Source: PLoS One - February 22, 2024 Category: Biomedical Science Authors: Supattra Rungmaitree Source Type: research
My Way: development and preliminary evaluation of a novel delivery system for PrEP and other sexual health needs of young women in Western Kenya
CONCLUSIONS: My Way is a promising delivery system for PrEP and other sexual health services among young women in Western Kenya. We found high feasibility and acceptability. PrEP use was modest, but higher with My Way compared to SoC. Long-acting PrEP formulations may overcome important barriers to PrEP use and should be explored in combination with the My Way delivery model.PMID:38379132 | DOI:10.1002/jia2.26217 (Source: Journal of the International AIDS Society)
Source: Journal of the International AIDS Society - February 21, 2024 Category: Infectious Diseases Authors: Jessica E Haberer Kevin Oware Lawrence Juma Bernard Nyerere Vincent Momanyi Josephine Odoyo Lindsey Garrison Julita Bhagat Nicholas Musinguzi Jared M Baeten Aaron Siegler Elizabeth A Bukusi Source Type: research
My Way: development and preliminary evaluation of a novel delivery system for PrEP and other sexual health needs of young women in Western Kenya
CONCLUSIONS: My Way is a promising delivery system for PrEP and other sexual health services among young women in Western Kenya. We found high feasibility and acceptability. PrEP use was modest, but higher with My Way compared to SoC. Long-acting PrEP formulations may overcome important barriers to PrEP use and should be explored in combination with the My Way delivery model.PMID:38379132 | PMC:PMC10879470 | DOI:10.1002/jia2.26217 (Source: Journal of the International AIDS Society)
Source: Journal of the International AIDS Society - February 21, 2024 Category: Infectious Diseases Authors: Jessica E Haberer Kevin Oware Lawrence Juma Bernard Nyerere Vincent Momanyi Josephine Odoyo Lindsey Garrison Julita Bhagat Nicholas Musinguzi Jared M Baeten Aaron Siegler Elizabeth A Bukusi Source Type: research
